JeanMarie Guenot, with over two decades of experience, is a renowned name in biotechnology and pharmaceutical industry. Due to his extensive experience with the national/multinational firm at the different key position made him an ideal candidate to be the CEO and president of a well-known name Amphivena Therapeutics, Inc. This company is famous because of its ground-breaking therapies and treatment for hematologic malignancies.
Before becoming CEO and President in Amphivena at https://www.crunchbase.com/person/jeanmarie-guenot, she worked for SKS Ocular and assisted it to become a company from scratch and that was a crucial turn in her life that made him believe in herself that she can achieve whatever she want with dedication and hard work. She also worked for Hoffmann-La Roche in Shanghai and Basel as a business advisor, and Jeanmarie Guenot also held a position for VP at PDL BioPharma, where she led major mergers, licensing alliance and acquisitions management deals. Her professional career from at Hoffmann-La Roche to CEO for Amphivena Therapeutics is full of hard work, devotion and dedication and very few normally get triumph in such tough time.
According to businesswire.com, JeanMarie Guenot trained in medicinal and physical chemistry, with emphasize in quantum semi-empirical and mechanical techniques for protein structure prediction, molecular dynamics, NMR refinement, X-ray and drug design. She completed her Master in Business Administration from The Wharton School that affiliated with Pennsylvania University, following her Ph.D. from the California University.
Amphivena Therapeutics, Inc is researching company that always works hard to find new and more effective cures for different diseases such as Hodgkin/non-Hodgkin lymphoma. The extensive background of JeanMarie Guenot in pharmaceutical and biotechnology industry has made her an ideal candidate to lead this company because of her experience in with different departments such as pharmaceutical R&D, commercial development, business development, corporate, alliance, and much more.
And that’s because to combine the expertise, strengths, and resources in one integrated and focused network that is passionate and committed to finding the most innovative therapies for the patients to help humanity.